StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie lupron (leuprolide) [legacy through FY21] — U.S. reported growth YoY (%) (%)

Form 8-K Key Product Revenues Schedule

QuarterlyAnnual
Latest, Q4 2021
6.1%
Period ended Dec 31, 2021
Change on a year earlier
+25.8 pts
-19.7% in Q4 2020
History
17 quarters
Since Q4 2017
Sources
17
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLupron (leuprolide) [legacy through FY21] — U.S. reported growth YoY (%) (%)Year on yearSource
Q4 2021Dec 31, 20216.1%+25.8 ptsForm 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗
Q3 2021Sep 30, 202135.7%+83.3 ptsForm 8-K (abbv-20210930xexhibit991.htm, filed 2021-10-29) ↗
Q2 2021Jun 30, 2021-10.2%-10.1 ptsForm 8-K (abbv-20210630xexhibit991.htm, filed 2021-07-30) ↗
Q1 2021Mar 31, 2021-12.1%-14.2 ptsForm 8-K (abbv-20210331xexhibit991.htm, filed 2021-04-30) ↗
Q4 2020Dec 31, 2020-19.7%-8.4 ptsForm 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗
Q3 2020Sep 30, 2020-47.6%-56.2 ptsForm 8-K (abbv-20200930xex991.htm, filed 2020-10-30) ↗
Q2 2020Jun 30, 2020-0.1%+6.3 ptsForm 8-K (abbv-20200630xexhibit991.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 20202.1%-5.3 ptsForm 8-K (abbv-20200331xexhibit9.htm, filed 2020-05-01) ↗
Q4 2019Dec 31, 2019-11.3%-19.6 ptsForm 8-K (abbv-20191231xexhibit9.htm, filed 2020-02-07) ↗
Q3 2019Sep 30, 20198.6%+1.0 ptsForm 8-K (abbv-20190930xexhibit991.htm, filed 2019-11-01) ↗
Q2 2019Jun 30, 2019-6.4%-10.7 ptsForm 8-K (abbv-20190630xexhibit991.htm, filed 2019-07-26) ↗
Q1 2019Mar 31, 20197.4%-7.4 ptsForm 8-K (abbv-20190331xexhibit991.htm, filed 2019-04-25) ↗
Q4 2018Dec 31, 20188.3%+6.8 ptsForm 8-K (abbv-20181231xexhibit991.htm, filed 2019-01-25) ↗
Q3 2018Sep 30, 20187.6%–Form 8-K (abbv-20180930xexhibit991.htm, filed 2018-11-02) ↗
Q2 2018Jun 30, 20184.3%–Form 8-K (abbv-20180630xexhibit991.htm, filed 2018-07-27) ↗
Q1 2018Mar 31, 201814.8%–Form 8-K (abbv-20180331xexhibit991cl.htm, filed 2018-04-26) ↗

Cite this data

StockData. (2026). AbbVie Lupron (leuprolide) [legacy through FY21] — U.S. reported growth YoY (%) (%), quarterly Q4 2017–Q4 2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lupron_us_rep_yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.